Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult…
5 analysts rate KPTI Buy on consensus.
Consensus price target: $7.25 (+1227.84% upside from $0.55)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Abate Kristin Chief Accounting Officer | Oct 1, 2026 | Sale | 378 | $449.82 |
| Abate Kristin Chief Accounting Officer | Sep 1, 2026 | Sale | 19 | $38.38 |
| Poulton Stuart EVP, Chief Development Officer | Jul 28, 2026 | Sale | 189 | $1.34K |
| Paulson Richard A. director, President and CEO | May 14, 2026 | Sale | 2,203 | $20.93K |
| Abate Kristin Chief Accounting Officer | May 14, 2026 | Sale | 53 | $503.5 |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $146.07M | +0.57% | $-196.04M |
| 2024 | $145.24M | -0.55% | $-76.42M |
| 2023 | $146.03M | -7.03% | $-143.1M |
Stock data for KPTI: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics